Search research articles
Contact Us
Filters
Showing results (511-520 of 520) with videos related to
Page
of 52
Sort By:
You have reached the last page of results.
This site can display upto 520 results.
Seminars in Nuclear Medicine
|
April 10, 2007
Age-related structural and functional changes in the breast: multimodality correlation with digital mammography, computed tomography, magnetic resonance imaging, and positron emission tomography
Richard G Abramson, Ayse Mavi, Tevfik Cermik, et al.
Molecular Imaging and Biology
|
September 6, 2023
Intricacies in the Preparation of Patient Doses of [<sup>177</sup>Lu]Lu-Rituximab and [<sup>177</sup>Lu]Lu-Trastuzumab Using Low Specific Activity [<sup>177</sup>Lu]LuCl<sub>3</sub>: Methodological Aspects
Avik Chakraborty, Arpit Mitra, Sudeep Sahu, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
September 15, 2017
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use <sup>177</sup>Lu-DOTA-TATE: The Intricate Radiochemistry Aspects
Anupam Mathur, Vrinda Prashant, Navin Sakhare, et al.
Journal of Gastrointestinal Cancer
|
June 14, 2024
Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors
Saneya A Pandrowala, Deeksha Kapoor, Aditya Kunte, et al.
American Journal of Nuclear Medicine and Molecular Imaging
|
September 15, 2020
One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [<sup>177</sup>Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting
Sandip Basu, Sudipta Chakraborty, Rahul V Parghane, et al.
Frontiers in Endocrinology
|
November 29, 2023
Association of <i>Cutibacterium acnes</i> with human thyroid cancer
Vaishakhi Trivedi, Vanita Noronha, Peddagangannagari Sreekanthreddy, et al.
BMC Cancer
|
October 29, 2025
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Ameya D Puranik, Indraja D Dev, Sushil Yadav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2023
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Jaydira Del Rivero, Kimberly Perez, Erin B Kennedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
Abhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
JCO Oncology Practice
|
May 9, 2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Kimberly Perez, Jaydira Del Rivero, Erin B Kennedy, et al.
Page
of 52
Search research articles
Search
Showing results (511-520 of 520) with videos related to
Sort By:
Page
of 52
You have reached the last page of results.
This site can display upto 520 results.
Seminars in Nuclear Medicine
|
April 10, 2007
Age-related structural and functional changes in the breast: multimodality correlation with digital mammography, computed tomography, magnetic resonance imaging, and positron emission tomography
Richard G Abramson, Ayse Mavi, Tevfik Cermik, et al.
Molecular Imaging and Biology
|
September 6, 2023
Intricacies in the Preparation of Patient Doses of [<sup>177</sup>Lu]Lu-Rituximab and [<sup>177</sup>Lu]Lu-Trastuzumab Using Low Specific Activity [<sup>177</sup>Lu]LuCl<sub>3</sub>: Methodological Aspects
Avik Chakraborty, Arpit Mitra, Sudeep Sahu, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
September 15, 2017
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use <sup>177</sup>Lu-DOTA-TATE: The Intricate Radiochemistry Aspects
Anupam Mathur, Vrinda Prashant, Navin Sakhare, et al.
Journal of Gastrointestinal Cancer
|
June 14, 2024
Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors
Saneya A Pandrowala, Deeksha Kapoor, Aditya Kunte, et al.
American Journal of Nuclear Medicine and Molecular Imaging
|
September 15, 2020
One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [<sup>177</sup>Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting
Sandip Basu, Sudipta Chakraborty, Rahul V Parghane, et al.
Frontiers in Endocrinology
|
November 29, 2023
Association of <i>Cutibacterium acnes</i> with human thyroid cancer
Vaishakhi Trivedi, Vanita Noronha, Peddagangannagari Sreekanthreddy, et al.
BMC Cancer
|
October 29, 2025
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Ameya D Puranik, Indraja D Dev, Sushil Yadav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2023
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Jaydira Del Rivero, Kimberly Perez, Erin B Kennedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
Abhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
JCO Oncology Practice
|
May 9, 2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Kimberly Perez, Jaydira Del Rivero, Erin B Kennedy, et al.
Page
of 52